Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Jordi Martínez‐Quintanilla(Vall d'Hebron Institute of Oncology), McAllister Milly
Cited by 15
Related Papers
TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence
|Journal of Clinical Investigation|2018|108